In addition to enhancing AML cell deletion by phagocytic cells and NK cells, LILRB4 antagonism is expected to promote activation of T cells, subsequently enhancing their capacity to eliminate malignant cells (78, 83, 84). This evidence concerns the gene LILRB4 and acute myeloid leukemia.